RP Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-3,846,154
| Closed | -$28.8M | – | 1 |
|
|
2025
Q1 | $28.8M | Hold |
3,846,154
| – | – | 20.78% | 3 |
|
|
2024
Q4 | $29.2M | Hold |
3,846,154
| – | – | 12.84% | 3 |
|
|
2024
Q3 | $29.2M | Hold |
3,846,154
| – | – | 12.84% | 3 |
|
|
2024
Q2 | $23.8M | Hold |
3,846,154
| – | – | 13.29% | 3 |
|
|
2024
Q1 | $19.5M | Hold |
3,846,154
| – | – | 10.85% | 2 |
|
|
2023
Q4 | $23M | Hold |
3,846,154
| – | – | 15.49% | 2 |
|
|
2023
Q3 | $27.2M | Hold |
3,846,154
| – | – | 26.28% | 2 |
|
|
2023
Q2 | $27.1M | Hold |
3,846,154
| – | – | 27.82% | 2 |
|
|
2023
Q1 | $32.1M | Hold |
3,846,154
| – | – | 44.43% | 2 |
|
|
2022
Q4 | $44.2M | Hold |
3,846,154
| – | – | 52% | 1 |
|
|
2022
Q3 | $48.5M | Hold |
3,846,154
| – | – | 22.39% | 2 |
|
|
2022
Q2 | $40.7M | Hold |
3,846,154
| – | – | 16.07% | 3 |
|
|
2022
Q1 | $62.5M | Hold |
3,846,154
| – | – | 25.44% | 2 |
|
|
2021
Q4 | $43M | Buy |
+3,846,154
| New | +$43M | 18% | 2 |
|